Damora Therapeutics logo

Damora Therapeutics

DMRA | NASDAQ
Chart Builder DCF Calculator
$22.50
+$0.90 (+4.17%)
At close: Nov 16, 2026, 4:00 PM ET
$22.06
-$0.44 (-1.96%)
After-hours: Nov 16, 2026, 7:30 PM ET
+4.17%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
27.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #866/1021 (Top 85%)

Key Statistics

Market Data

Market Cap $1.39B
1D Range
21.33 23.75
52W Range
16.31 34.14

Valuation (TTM)

PE -0.18
PB 2.81
EV/EBITDA -2.88

Valuation (NTM)

Forward PE N/A
Forward PEG -0.05
Price Target $55.00
Loading financial charts...

Profile

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a inves...

Sector Healthcare
Industry Biotechnology
Employees 7
IPO Date Oct 29, 2020
Fiscal Year January - December

Latest News

Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

12 days ago · globenewswire.com

Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis

3 months ago · globenewswire.com

Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
Damora Announces Redomestication from Delaware to Cayman Islands

4 months ago · globenewswire.com

Damora Announces Redomestication from Delaware to Cayman Islands
Damora Therapeutics: Well-Funded Moonshot For CALR Mutations

6 months ago · seekingalpha.com

Damora Therapeutics: Well-Funded Moonshot For CALR Mutations
How Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1%

7 months ago · zacks.com

How Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1%

Analyst Summary

# of Analysts
3
Consensus
Buy
Price Target
$55.00
Upside
+144.44%
Buy (3)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.